Overview

Phase I Clinical Trial of TQC2731 Injection

Status:
Not yet recruiting

Trial end date:
2023-08-25

Target enrollment:

Participant gender:

Summary

This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.

Phase:

Phase 1

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.